General contact

Main switchboard

+41 61 324 11 11
+41 61 324 80 01
Monday - Friday,
8:30 a.m. - 5:00 p.m. GMT+1

US switchboard

+1 862 778 21 00
Monday - Friday,
8:30 a.m. - 5:00 p.m. EST


Global Media Relations
Eric Althoff
Basel, Switzerland

+41 61 324 7999


Investor Relations

Monday - Friday,
8:30 a.m. - 5:30 p.m. GMT+1
(Central European Time)

Reporting side effects

Report a suspected side effect (also known as an adverse event) related to a Novartis Pharmaceutical drug or a Novartis Vaccine.

Reporting side effects

pane 4 content


Leading the way in eye care

Eye patient

Alcon, the second largest division of Novartis, is the global leader in eye care proudly reaching more than 90 percent of the globe – operating in more than 75 countries, serving 180 markets. Alcon is helping people see the world better through state-of-the-art surgical, pharmaceutical and vision care products. At Alcon, we enhance sight to enhance life.

Driving patient outcomes through cutting-edge innovation

Alcon’s leadership is grounded in cutting-edge innovation and breakthrough technology, transforming the way we treat eye diseases and conditions. Offering a broad spectrum of eye care products that are organized into three businesses: Surgical, Pharmaceutical and Vision Care.

Surgical – Alcon offers the industry’s most complete line of ophthalmic surgical products, enabling surgeons to achieve the best results for their patients. Our surgical portfolio includes technologies and devices for cataract, retinal, glaucoma and refractive surgery, as well as advanced technology intraocular lenses (ATIOLs) to treat cataracts and refractive errors, like presbyopia and astigmatism. We also provide advanced viscoelastics, surgical solutions, surgical packs, and other disposable products for cataract and vitreoretinal surgery.

Ophthalmic Pharmaceuticals – The Alcon ophthalmic pharmaceuticals portfolio includes treatment options for elevated intraocular pressure caused by glaucoma, anti-inflammatories and anti-infectives to aid in the treatment of bacterial infections and bacterial conjunctivitis, ophthalmic solutions to treat inflammation and pain associated with ocular surgery, as well as eye inflammation and infection following cataract surgery. The product portfolio also includes treatments for vitreomacular adhesion, vitreomacular traction among other retinal diseases, eye and nasal allergy treatments, and over-the-counter dry eye relief and ocular vitamins.

Vision Care – Our Vision Care portfolio offers daily disposable, monthly replacement and color-enhancing contact lenses for comfortable and convenient vision correction options. We also have a complete line of contact lens care products. These include multi-purpose and hydrogen-peroxide based solutions to clean, rinse and disinfect contact lenses; rewetting drops to provide added comfort throughout the day; and daily protein remover that removes protein deposits from lenses.

Commitment to patients

Alcon continues to set new standards for innovation by developing new products and technologies to treat a broad range of eye diseases and conditions affecting people of all ages around the globe. About 800 million people worldwide live with some form of vision impairment, and nearly 40 million of them are blind. Yet at least 90% of vision problems or blindness can be prevented, treated or cured, provided people have access to care. We believe everyone deserves access to quality eye care regardless of economic status or where they live in the world. Patients are at the center of everything we do and at the heart of our commitment to helping people see better.